Latest Oncology News

EC-18 Reduces Duration and Incidence of Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer

EC-18 Reduces Duration and Incidence of Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer

October 21st 2021

Kristi Rosa

Treatment with the small molecule oral immunomodulator EC-18 resulted in a reduction in both the duration and incidence of severe oral mucositis in patients with head and neck cancer who are undergoing concurrent chemoradiation.

Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients

Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients

October 21st 2021

OncLive Staff

Dr. Abid discusses immune-compromising factors that are indigenous to CAR T-cell therapy recipients, the immunogenic potential of different COVID-19 vaccines, determinants of vaccine responses, and the potential need for booster vaccine dosing in this population.

TG-1701 Induces Strong Response Rates, Fewer AEs in Relapsed/Refractory CLL

TG-1701 Induces Strong Response Rates, Fewer AEs in Relapsed/Refractory CLL

October 21st 2021

Maggie Tibbitt

Chan Cheah, MBBS, discusses TG-1701 as a more target-specific BTK inhibitor, the outcomes in response rates in the cohorts of the trial, and where future research is headed with this agent.

Mutational Status Is Associated With Time to First Treatment in Newly Diagnosed CLL

Mutational Status Is Associated With Time to First Treatment in Newly Diagnosed CLL

October 21st 2021

Caroline Seymour

The presence of at least 1 mutation captured by next-generation sequencing was associated with a shorter time to first treatment among patients with newly diagnosed chronic lymphocytic leukemia, particularly those with mutations in POT1, ATM, FBXW7, and MYD88 genes.

Nivolumab/Chemo Approved in Europe for HER2– Advanced or Metastatic Gastric, GEJ, or Esophageal Adenocarcinoma

Nivolumab/Chemo Approved in Europe for HER2– Advanced or Metastatic Gastric, GEJ, or Esophageal Adenocarcinoma

October 21st 2021

Kristi Rosa

The European Commission has approved nivolumab plus fluoropyrimidine- and platinum-based chemotherapy for the frontline treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma whose tumors have a PD-L1 combined positive score of 5 or higher.

Latest Oncology Videos

All Oncology News

Optellum, Johnson & Johnson Launch Strategic Collaboration in Lung Cancer

September 26th 2021

Jason Harris

Optellum and the Lung Cancer Initiative at Johnson & Johnson plan to use Optellum’s artificial intelligence-based decision support software in an effort to increase lung cancer survival rates via disease prevention and early intervention.

No-Cost Counseling Can Address Psychosocial Needs of Patients With Cancer

September 25th 2021

Denise Myshko

Counseling, psychotherapy, and mental health services provide the opportunity to develop coping skills and inspire hope; however, patients often experience hurdles to accessing such care. Among these obstacles are cost, unawareness that programs exist, the COVID-19 pandemic, and other external factors.

Dr. Shah on Key Findings From the KarMMa Trial in Multiple Myeloma

September 24th 2021

Nina Shah, MD

Nina Shah, MD, discusses key findings from the phase 2 KarMMA trial in relapsed/refractory multiple myeloma.

Dr. Agarwal on the Design of the AMPLITUDE Trial in mCSPC

September 24th 2021

Neeraj Agarwal, MD

Neeraj Agarwal, MD, discusses the design of the ongoing phase 3 AMPLITUDE trial in metastatic castration-sensitive prostate cancer.

Dr. Cohen on the Shortcomings of Trials Evaluating Cytoreductive Surgery and HIPEC in CRC

September 24th 2021

Stacey A. Cohen, MD

Stacey A. Cohen, MD, discusses the shortcomings of clinical trials evaluating cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer.

Dr. Spira on the Impact of the PACIFIC-R Trial in Unresectable Stage III NSCLC

September 24th 2021

Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

Alexander I. Spira, MD, PhD, FACP, discusses the impact of the PACIFIC-R trial in patients with unresectable stage III non–small cell lung cancer.

Dr. Li on the Results of the DESTINY-Lung01 Trial in HER2+ Metastatic NSCLC

September 24th 2021

Bob T. Li, MD, MPH

Bob T. Li, MD, PhD, MPH, discusses the results of the phase 2 DESTINY-Lung01 trial in HER2-positive metastatic non–small cell lung cancer.

Prolonged Overall Survival Observed With Oral Decitabine/Cedazuridine in MDS and CMML

September 24th 2021

Jessica Hergert

Updated data from the phase 3 ASCERTAIN trial demonstrated that the oral, fixed-duration combination of decitabine and cedazuridine induced a median overall survival of 31.7 months in patients with intermediate- and high-risk myelodysplastic syndrome, including chronic myelomonocytic leukemia.

Dr. Harbeck on Key Results From the WSG ADAPT-TP Trial in HER2+, HR+ Breast Cancer

September 24th 2021

Nadia Harbeck, MD, PhD

Nadia Harbeck, MD, PhD, discusses the key results from the phase 2 WSG ADAPT-TP trial in patients with HER2-positive, hormone receptor–positive early-stage breast cancer.

Dr. Garassino on the Clinical Implications of Tepotinib in METex14-Altered NSCLC

September 24th 2021

Marina Chiara Garassino, MD

Marina Chiara Garassino, MD, professor of Medicine, Hematology and Oncology, The University of Chicago Department of Medicine, discusses the clinical implications of the phase 2 VISION trial evaluating patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.

Targeted Therapy Drives Improves Outcomes Throughout Lung Cancer Subtypes

September 24th 2021

Caroline Seymour

The availability of targeted agents for patients with advanced non–small cell lung cancer who harbor mutations in EGFR, RET, MET, and KRAS has not only led to improved outcomes, but provided greater flexibility for treatment-naïve and pretreated populations, with the possibility of enhanced intracranial activity.

Janjigian Spotlights Significance of Nivolumab/Chemo Approval for Frontline Gastric Cancer

September 24th 2021

Ryan Scott

Yelena Y. Janjigian, MD, further discusses the clinical significance of the FDA approval of nivolumab plus chemotherapy in the frontline treatment of patients with gastric cancer.

Dual-Targeted CAR T-Cell Therapy Shows Intriguing Activity in Relapsed/Refractory B-Cell Malignancies

September 24th 2021

Caroline Seymour

Treatment with CD19-22.BB.z-CAR, a bispecific CAR T-cell therapy targeting CD19 and CD22, elicited high response rates and was well tolerated in adult patients with relapsed/refractory, CD19-positive B-cell acute lymphoblastic leukemia and large B-cell lymphoma.

Addition of Olaparib to Abiraterone Improves rPFS in mCRPC

September 24th 2021

Courtney Marabella

Olaparib in combination with abiraterone acetate demonstrated a significant and clinically meaningful improvement in radiographic progression-free survival vs abiraterone alone as a first-line treatment for patients with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations.

Hollings Cancer Center Researcher Awarded DoD Grant to Investigate New Approaches to Treating Colon Cancer

September 24th 2021

MUSC Hollings Cancer Center researchers received a grant from the Department of Defense to investigate how dietary fat affects the development of colon cancer and to find more effective methods of treatment.

See All News